Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 10/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 10/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 10/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 10/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 10/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 10/20 | 0.46 |
| ▸ | CTSK | P43235 | 6/20 | 0.45 |
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | CTSH | P09668 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529760 | 0.93 | CTSK (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5530609 | 0.84 | CTSK (0.52) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL5525962 | 0.84 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5671344 | 0.83 | REN (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5526359 | 0.81 | CTSK (0.60) | CTSKCTSSCTSLCTSBMETAP2 | |
| SCHEMBL5527029 | 0.80 | CTSK (0.54) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL5523324 | 0.80 | CTSK (0.56) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL5530376 | 0.79 | CTSK (0.58) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL5518465 | 0.79 | CTSK (0.54) | CTSKCTSSCTSLCTSBMETAP2 | |
| SCHEMBL5520695 | 0.79 | CTSK (0.55) | CTSKCTSSCTSLCTSBCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | AXYS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | AXYS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | PSEN1 1245/4885PSEN2 1058/4885APH1B 728/4885 |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | CAPNS1, CTSS, CTSV | PSEN1 4065/4885PSEN2 3710/4885APH1B 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.